CD63 and melanoma: All these results suggest that these cytopermeable peptides could offer an advantageous therapeutic tool to selectively block tetraspanin function, although, since they are dependent on the expression of the targeted tetraspanin, latest stages of melanoma, which usually downregulate both CD9 and CD63, may become refractory to treatment.